Summary
28.78 -0.32(-1.10%)05/20/2024
Supernus Pharmaceuticals Inc (SUPN)
Supernus Pharmaceuticals Inc (SUPN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.37 | 3.59 | -0.76 | 14.31 | 30.55 | -15.33 | -15.72 | 480.07 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 31.15 | |
| Open | 30.56 | |
| High | 31.31 | |
| Low | 30.46 | |
| Volume | 356,994 | |
| Change | 0.72 | |
| Change % | 2.37 | |
| Avg Volume (20 Days) | 253,144 | |
| Volume/Avg Volume (20 Days) Ratio | 1.41 | |
| 52 Week Range | 22.00 - 38.08 | |
| Price vs 52 Week High | -18.20% | |
| Price vs 52 Week Low | 41.59% | |
| Range | 1.93 | |
| Gap Up/Down | -0.85 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,582 | |
| EBIDTA | 98,262,000 | |
| PE Ratio | 1,503.5000 | |
| PEG Ratio | 1.4700 | |
| WallStreet Target Price | 40.50 | |
| Book Value | 16.8400 | |
| Earnings Per Share | 0.0200 | |
| EPS Estimate Current Quarter | 0.5500 | |
| EPS Estimate Next Quarter | 0.3800 | |
| EPS Estimate Current Year | 1.6400 | |
| EPS Estimate Next Year | 1.9500 | |
| Diluted EPS (TTM) | 0.0200 | |
| Revenues | ||
| Profit Marging | 0.0022 | |
| Operating Marging (TTM) | 0.1156 | |
| Return on asset (TTM) | 0.0056 | |
| Return on equity (TTM) | 0.0015 | |
| Revenue TTM | 607,521,024 | |
| Revenue per share TTM | 11.1400 | |
| Quarterly Revenue Growth (YOY) | -0.0180 | |
| Quarterly Earnings Growth (YOY) | -0.9590 | |
| Gross Profit (TTM) | 580,017,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 1,503.5000 | |
| Forward PE | 20.1613 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.7962 | |
| Revenue Enterprise Value | 2.3733 | |
| EBITDA Enterprise Value | 16.0128 | |
| Shares | ||
| Shares Outstanding | 54,735,000 | |
| Shares Float | 47,706,440 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.13 | |
| Insider (%) | 5.12 | |
| Institutions (%) | 108.39 | |
05/16 19:40 EST - prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
NEW YORK , May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
NEW YORK , May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
05/09 16:05 EST - globenewswire.com
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, May 23, 2024, at 4:30 p.m. ET to review interim data from the open-label Phase IIa study of SPN-817 for treatment-resistant seizures.
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, May 23, 2024, at 4:30 p.m. ET to review interim data from the open-label Phase IIa study of SPN-817 for treatment-resistant seizures.
05/08 20:28 EST - seekingalpha.com
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2024 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Stacy Ku - TD Cowen Jack Padovano - Stifel Operator Good afternoon, and welcome to the Supernus Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2024 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Stacy Ku - TD Cowen Jack Padovano - Stifel Operator Good afternoon, and welcome to the Supernus Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
05/08 20:01 EST - zacks.com
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
05/08 16:05 EST - globenewswire.com
Supernus Announces First Quarter 2024 Financial Results
ROCKVILLE, Md., May 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter of 2024 and associated Company developments.
Supernus Announces First Quarter 2024 Financial Results
ROCKVILLE, Md., May 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter of 2024 and associated Company developments.
05/07 10:20 EST - zacks.com
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Supernus (SUPN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Supernus (SUPN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
05/07 10:00 EST - prnewswire.com
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America
MEXICO CITY , May 7, 2024 /PRNewswire/ -- M8 Pharmaceuticals, an Acino company ('M8') announces that the company has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ('Supernus'), a biopharmaceutical company focused on the development and commercialization of products for the treatment of diseases of the central nervous system (CNS), to seek regulatory approval and commercialize Qelbree® (Viloxazine XR) under M8's trademark in Latin America. Qelbree® (viloxazine extended-release capsule) which is approved in the United States is an extended-release formulation of viloxazine, a selective norepinephrine reuptake inhibitor to treat attention deficit hyperactivity disorder (ADHD) in adults and children 6 years of age and older.
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America
MEXICO CITY , May 7, 2024 /PRNewswire/ -- M8 Pharmaceuticals, an Acino company ('M8') announces that the company has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ('Supernus'), a biopharmaceutical company focused on the development and commercialization of products for the treatment of diseases of the central nervous system (CNS), to seek regulatory approval and commercialize Qelbree® (Viloxazine XR) under M8's trademark in Latin America. Qelbree® (viloxazine extended-release capsule) which is approved in the United States is an extended-release formulation of viloxazine, a selective norepinephrine reuptake inhibitor to treat attention deficit hyperactivity disorder (ADHD) in adults and children 6 years of age and older.
05/01 20:17 EST - businesswire.com
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) investors concerning the Company's possible violations of federal securities laws. On April 8, 2024, Supernus announced that the FDA had issued a Complete Response Letter (“CRL”) in response to the Company's New Drug Application for its Parkinson's disease treatment, SPN-830. The CRL stated that “the review cycle for t.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) investors concerning the Company's possible violations of federal securities laws. On April 8, 2024, Supernus announced that the FDA had issued a Complete Response Letter (“CRL”) in response to the Company's New Drug Application for its Parkinson's disease treatment, SPN-830. The CRL stated that “the review cycle for t.
05/01 08:00 EST - globenewswire.com
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
ROCKVILLE, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Actress, author, podcaster, and mother of two, Busy Philipps is teaming up with Supernus Pharmaceuticals to share her personal journey with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses in adults – as well as her experience with Qelbree (viloxazine extended-release capsules), a non-stimulant medication for the treatment of ADHD.3
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
ROCKVILLE, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Actress, author, podcaster, and mother of two, Busy Philipps is teaming up with Supernus Pharmaceuticals to share her personal journey with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses in adults – as well as her experience with Qelbree (viloxazine extended-release capsules), a non-stimulant medication for the treatment of ADHD.3
04/29 19:20 EST - businesswire.com
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 8, 2024, Supernus announced that the FDA had issued a Complete Response Letter (“CRL”) in response to the Company's New Drug Application for its Parkins.
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 8, 2024, Supernus announced that the FDA had issued a Complete Response Letter (“CRL”) in response to the Company's New Drug Application for its Parkins.
04/24 16:05 EST - globenewswire.com
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expects to report financial and business results for the first quarter of 2024 after the market closes on Wednesday, May 8, 2024.
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expects to report financial and business results for the first quarter of 2024 after the market closes on Wednesday, May 8, 2024.
04/08 08:00 EST - globenewswire.com
Supernus Provides Regulatory Update for SPN-830
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830. SPN-830 is an investigational apomorphine infusion device for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson's disease (PD) under U.S. Food and Drug Administration (FDA) review.
Supernus Provides Regulatory Update for SPN-830
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830. SPN-830 is an investigational apomorphine infusion device for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson's disease (PD) under U.S. Food and Drug Administration (FDA) review.
03/06 16:30 EST - globenewswire.com
Supernus to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences:
Supernus to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences:
02/28 16:30 EST - globenewswire.com
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET at the Marriott Copley Place in Boston, Mass.
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET at the Marriott Copley Place in Boston, Mass.
02/27 21:41 EST - seekingalpha.com
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript
02/27 20:31 EST - zacks.com
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
02/27 19:51 EST - zacks.com
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.43 per share a year ago.
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.43 per share a year ago.